Argos Therapeutics Inc (NASDAQ:ARGS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday,MarketBeat.Com reports. The firm currently has a $3.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target points to a potential downside of 7.12% from the stock’s current price.
Argos Therapeutics, Inc. (NASDAQ:ARGS) belongs to Healthcare sector. Its weekly performance is -24.26%. On last trading day company shares ended up at $3.56. Argos Therapeutics, Inc. (NASDAQ:ARGS) distance from 50-day simple moving average (SMA50) is 0.50%.
Bovie Medical Corporation (NYSEMKT:BVX) announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2015 on Thursday March 17, 2016 after market close.
Bovie Medical Corporation (NYSEMKT:BVX) shares increased 16.32% in last trading session and ended the day at $2.21. BVX Gross Margin is 40.10% and its return on assets is 13.30%. Bovie Medical Corporation (NYSEMKT:BVX) quarterly performance is 16.32%.
Biogen Inc. (NASDAQ:BIIB) is launching an initiative developed with the assistance of clinical experts — the 1MSg campaign — to educate and encourage multiple sclerosis (MS) patients to make disease management decisions that are well-informed and based on the latest scientific research.
On 25 February, Biogen Inc. (NASDAQ:BIIB) shares increased 1.99% and was closed at $262.35. BIIB EPS growth in last 5 year was 31.20%. Biogen Inc. (NASDAQ:BIIB) year to date (YTD) performance is -14.36%.
On 22 February, NanoViricides, Inc. (NYSEMKT:NNVC) announced that information on its novel, proprietary anti-virus platform technology has been published in the book “Handbook of Clinical Nanomedicine, Vol. 1. Nanoparticles, Imaging, Therapy, and Clinical Applications”, a CRC Press publication. The chapter entitled “Nanoviricides: Targeted Anti-Viral Nanomaterials” provides an in-depth presentation of the NanoViricides platform technology, evidence for how nanoviricides® are believed to act plus dramatic results of nanoviricides specifically targeting certain viral diseases, such as Influenza.
NanoViricides, Inc. (NYSEMKT:NNVC) ended the last trading day at $2.69. Company weekly volatility is calculated as 15.23% and price to cash ratio as 5.52. NanoViricides, Inc. (NYSEMKT:NNVC) showed a weekly performance of 54.60%.
KeyCorp. (NYSE:KEY) announced that Don Kimble, Chief Financial Officer, and Chris Gorman, President of Key Corporate Bank, will present at the RBC Capital Markets Financial Institutions Conference in New York City on Tuesday, March 8, 2016, at 8:30 a.m. ET.
KeyCorp. (NYSE:KEY) shares advanced 1.42% in last trading session and ended the day at $10.69. KEY return on assets is 0.90%. KeyCorp. (NYSE:KEY) quarterly performance is -17.87%.